Should I buy or sell NeoGenomics stock right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NeoGenomics in the last twelve months. There are currently 2 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" NEO shares. View NEO analyst ratings or view top-rated stocks .

What is NeoGenomics' stock price target for 2024?

10 brokers have issued 1 year price targets for NeoGenomics' stock. Their NEO share price targets range from $17.00 to $24.00. On average, they predict the company's stock price to reach $19.50 in the next year. This suggests a possible upside of 43.7% from the stock's current price. View analysts price targets for NEO or view top-rated stocks among Wall Street analysts .

How have NEO shares performed in 2024?

NeoGenomics' stock was trading at $16.18 at the start of the year. Since then, NEO stock has decreased by 16.1% and is now trading at $13.57. View the best growth stocks for 2024 here .

When is NeoGenomics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 30th 2024. View our NEO earnings forecast .

How can I listen to NeoGenomics' earnings call?

NeoGenomics will be holding an earnings conference call on Tuesday, April 30th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link .

How were NeoGenomics' earnings last quarter?

NeoGenomics, Inc. (NASDAQ:NEO) released its quarterly earnings results on Tuesday, February, 20th. The medical research company reported ($0.02) EPS for the quarter, topping analysts' consensus estimates of ($0.07) by $0.05. The medical research company had revenue of $155.55 million for the quarter, compared to the consensus estimate of $152.90 million. NeoGenomics had a negative net margin of 14.87% and a negative trailing twelve-month return on equity of 4.13%.

What ETFs hold NeoGenomics' stock?

ETFs with the largest weight of NeoGenomics (NASDAQ:NEO) stock in their portfolio include SPDR S&P Health Care Services ETF (XHS) , Invesco S&P SmallCap Health Care ETF (PSCH) , WisdomTree BioRevolution Fund (WDNA) , First Trust Nasdaq Lux Digital Health Solutions ETF (EKG) and iShares U.S. Healthcare Providers ETF (IHF) . SPDR S&P 600 Small Cap ETF (SLY) .

What guidance has NeoGenomics issued on next quarter's earnings?

NeoGenomics issued an update on its first quarter 2024 earnings guidance on Wednesday, February, 21st. The company provided EPS guidance of for the period. The company issued revenue guidance of $148.0 million-$151.0 million, compared to the consensus revenue estimate of $149.4 million.

What is Douglas M. VanOort's approval rating as NeoGenomics' CEO?

116 employees have rated NeoGenomics Chief Executive Officer Douglas M. VanOort on Glassdoor.com . Douglas M. VanOort has an approval rating of 98% among the company's employees. This puts Douglas M. VanOort in the top 20% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of NeoGenomics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NeoGenomics investors own include Marvell Technology (MRVL) , NVIDIA (NVDA) , Alibaba Group (BABA) , Block (SQ) , Inseego (INSG) , PayPal (PYPL) , Micron Technology (MU) , Invitae (NVTA) , CRISPR Therapeutics (CRSP) and AbbVie (ABBV) .

Who are NeoGenomics' major shareholders?

NeoGenomics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Silverberg Bernstein Capital Management LLC (0.02%), Allspring Global Investments Holdings LLC (0.02%) and Banque Cantonale Vaudoise (0.01%). Insiders that own company stock include Alicia C Olivo, Bruce K Crowther , Douglas Matthew Brown , George Cardoza , Kathryn B Mckenzie , Mark Mallon , Robert J Shovlin and William Bonello. View institutional ownership trends .

How do I buy shares of NeoGenomics?

Shares of NEO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Does NeoGenomics have any subsidiaries?

The following companies are subsidiares of NeoGenomics: Clarient Inc., Clarient Diagnostic Services Inc, Clarient Inc, Cynogen Inc., GE Medical Holding AB., Genesis Acquisition Holding Corp, Genesis Acquisition Holdings Corp., Genoptix, Genoptix Inc., Inivata Inc., Inivata Limited, Inivata Limited., Minuet Diagnostics Inc., NeoGenomics Bioinformatics Inc., NeoGenomics Europe SA, NeoGenomics Foundation Inc, NeoGenomics Laboratories Inc, NeoGenomics Singapore Pte. Ltd, Path Labs LLC, Suzhou NeoGenomics Pharmaceutical Research Co. Limited, Trapelo Health, and Trapelo Health LLC. Read More

NASDAQ:NEO

NeoGenomics (NEO) Stock Price, News & Analysis

→ Strange new buyer driving up gold (From Stansberry Research) (Ad)

Free NEO Stock Alerts

$13.52

-0.25 (-1.82%)

(As of 02:39 PM ET)

Compare

Today's Range: $13.51
▼
$13.79
50-Day Range: $13.68
▼
$16.79
52-Week Range: $11.03
▼
$21.22

Volume: 353,378 shs
Average Volume: 896,258 shs
Market Capitalization: $1.73 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $19.50

Get NeoGenomics alerts:

NeoGenomics MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.80 Rating Score
Upside/Downside: 43.7% Upside
$19.50 Price Target
Short Interest: Bearish
5.67% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.51
Based on 2 Articles This Week
Insider Trading: Selling Shares
$38,702 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($0.20) to ($0.10) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.94 out of 5 stars

Medical Sector

708th out of 918 stocks

Testing Laboratories Industry

1st out of 1 stocks

3.4

Analyst's Opinion

Consensus Rating
NeoGenomics has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 8 buy ratings, 2 hold ratings, and no sell ratings.
Amount of Analyst Coverage
NeoGenomics has only been the subject of 4 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
5.67% of the outstanding shares of NeoGenomics have been sold short.
Short Interest Ratio / Days to Cover
NeoGenomics has a short interest ratio ("days to cover") of 7.9.
Change versus previous month
Short interest in NeoGenomics has recently decreased by 0.69%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
NeoGenomics does not currently pay a dividend.
Dividend Growth
NeoGenomics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for NEO.

2.0

News and Social Media Coverage

News Sentiment
NeoGenomics has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for NeoGenomics this week, compared to 3 articles on an average week.
Search Interest
Only 5 people have searched for NEO on MarketBeat in the last 30 days. This is a decrease of -55% compared to the previous 30 days.
MarketBeat Follows
5 people have added NeoGenomics to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, NeoGenomics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $38,702.00 in company stock.
Percentage Held by Insiders
Only 1.30% of the stock of NeoGenomics is held by insiders.
Percentage Held by Institutions
98.50% of the stock of NeoGenomics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for NeoGenomics are expected to grow in the coming year, from ($0.20) to ($0.10) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of NeoGenomics is -19.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of NeoGenomics is -19.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
NeoGenomics has a P/B Ratio of 1.84. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About NeoGenomics Stock (NASDAQ:NEO)

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.

NEO Stock Price History

30 days | 90 days | 365 days | Advanced Chart

NEO Stock News Headlines

April 19, 2024 | americanbankingnews.com

NeoGenomics, Inc. (NASDAQ:NEO) Receives Consensus Rating of "Moderate Buy" from Brokerages

April 18, 2024 | businesswire.com

NeoGenomics Announces Senior Leadership Promotions

April 19, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

April 9, 2024 | businesswire.com

NeoGenomics to Report First Quarter 2024 Financial Results on April 30, 2024

March 27, 2024 | businesswire.com

NeoGenomics Showcases Commitment to Transforming Cancer Patient Care at AACR 2024 Annual Meeting

March 21, 2024 | nasdaq.com

Commit To Purchase NeoGenomics At $10, Earn 9.1% Annualized Using Options

March 20, 2024 | msn.com

Neogenomics Pokes Up On Unveiling ESG Report

March 20, 2024 | businesswire.com

NeoGenomics Releases Inaugural Environmental, Social, and Governance (ESG) Report

April 19, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

March 14, 2024 | barrons.com

NeoGenomics Inc.

March 11, 2024 | au.finance.yahoo.com

Omics Lab Services Market Report 2024 - Innovations in Genomics and Big Data Analytics

March 1, 2024 | businesswire.com

NeoGenomics to Participate in the TD Cowen 44th Annual Health Care Conference

February 28, 2024 | finance.yahoo.com

Wall Street Analysts Predict a 29.57% Upside in NeoGenomics (NEO): Here's What You Should Know

February 23, 2024 | msn.com

NeoGenomics (NEO) Price Target Increased by 6.33% to 21.79

February 23, 2024 | finance.yahoo.com

NEO Mar 2024 10.000 put

February 22, 2024 | finance.yahoo.com

NeoGenomics Full Year 2023 Earnings: EPS Beats Expectations

February 21, 2024 | markets.businessinsider.com

Why Is Cancer Genetics Test-Focused NeoGenomics Stock Trading Higher Today?

February 21, 2024 | marketwatch.com

NeoGenomics Stock Rises on Earnings Beat, Upbeat Guidance

February 21, 2024 | msn.com

NeoGenomics shares jump after revenue forecast tops Street expectations

February 21, 2024 | finance.yahoo.com

NeoGenomics, Inc. (NASDAQ:NEO) Q4 2023 Earnings Call Transcript

February 21, 2024 | markets.businessinsider.com

Evaluating NeoGenomics: Insights From 4 Financial Analysts

February 21, 2024 | markets.businessinsider.com

Why NeoGenomics Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket

February 21, 2024 | finance.yahoo.com

Q4 2023 Neogenomics Inc Earnings Call

February 20, 2024 | finance.yahoo.com

NeoGenomics (NEO) Q4 Earnings and Revenues Beat Estimates

February 20, 2024 | finance.yahoo.com

NeoGenomics (NEO) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates

February 20, 2024 | benzinga.com

Recap: NeoGenomics Q4 Earnings

February 20, 2024 | sfgate.com

NeoGenomics: Q4 Earnings Snapshot

See More Headlines

Receive NEO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NeoGenomics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/20/2024
Today: 4/19/2024
Next Earnings (Confirmed): 4/30/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Testing laboratories
Sub-Industry: N/A
Current Symbol: NASDAQ:NEO
CUSIP: N/A
CIK: 1077183
Web: www.neogenomics.com
Phone: (239) 768-0600
Fax: 239-690-4237
Employees: 2,100
Year Founded: 2002

Price Target and Rating

Average Stock Price Target: $19.50
High Stock Price Target: $24.00
Low Stock Price Target: $17.00
Potential Upside/Downside: +44.2%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.80
Research Coverage: 10 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.70)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-87,970,000.00
Net Margins: -14.87%
Pretax Margin: -16.41%
Return on Equity: -4.13%
Return on Assets: -2.33%

Debt

Debt-to-Equity Ratio: 0.57
Current Ratio: 6.20
Quick Ratio: 5.95

Sales & Book Value

Annual Sales: $591.64 million
Price / Sales: 2.92
Cash Flow: $0.28 per share
Price / Cash Flow: 48.46
Book Value: $7.39 per share
Price / Book: 1.83

Miscellaneous

Outstanding Shares: 127,666,000
Free Float: 126,006,000
Market Cap: $1.73 billion
Optionable: Optionable
Beta: 1.10

Social Links

Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

Mr. Christopher Michael Smith BSc (Age 61)
CEO & Director
Comp: $3.52M
Mr. Jeffrey S. Sherman M.B.A. (Age 58)
Chief Financial Officer
Comp: $492.31k
Mr. Warren Stone (Age 51)
President of Clinical Division
Comp: $722.79k
Mr. Vishal Sikri (Age 47)
President of Pharma Services, President & Chief Commercial Officer Inivata
Comp: $1.21M
Gregory D. Aunan
Senior VP & Chief Accounting Officer
Ms. Kendra Sweeney
Vice President of Investor Relations & Communications
Ms. Alicia Olivo (Age 40)
General Counsel & Corporate Secretary
Mr. Hutan Hashemi J.D. (Age 45)
Chief Compliance Officer
Dr. Derek Lyle M.D.
Chief Medical Officer
Ms. Melody Harris Esq. (Age 58)
J.D., President of Enterprise Operations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

NEO Stock Analysis - Frequently Asked Questions

Should I buy or sell NeoGenomics stock right now?: 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NeoGenomics in the last twelve months. There are currently 2 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" NEO shares.
View NEO analyst ratings or view top-rated stocks.
What is NeoGenomics' stock price target for 2024?: 10 brokers have issued 1 year price targets for NeoGenomics' stock. Their NEO share price targets range from $17.00 to $24.00. On average, they predict the company's stock price to reach $19.50 in the next year. This suggests a possible upside of 43.7% from the stock's current price.
View analysts price targets for NEO or view top-rated stocks among Wall Street analysts.
How have NEO shares performed in 2024?: NeoGenomics' stock was trading at $16.18 at the start of the year. Since then, NEO stock has decreased by 16.1% and is now trading at $13.57.
View the best growth stocks for 2024 here.
When is NeoGenomics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 30th 2024.
View our NEO earnings forecast.
How can I listen to NeoGenomics' earnings call?: NeoGenomics will be holding an earnings conference call on Tuesday, April 30th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.
How were NeoGenomics' earnings last quarter?: NeoGenomics, Inc. (NASDAQ:NEO) released its quarterly earnings results on Tuesday, February, 20th. The medical research company reported ($0.02) EPS for the quarter, topping analysts' consensus estimates of ($0.07) by $0.05. The medical research company had revenue of $155.55 million for the quarter, compared to the consensus estimate of $152.90 million. NeoGenomics had a negative net margin of 14.87% and a negative trailing twelve-month return on equity of 4.13%.
What ETFs hold NeoGenomics' stock?: ETFs with the largest weight of NeoGenomics (NASDAQ:NEO) stock in their portfolio include SPDR S&P Health Care Services ETF (XHS), Invesco S&P SmallCap Health Care ETF (PSCH), WisdomTree BioRevolution Fund (WDNA), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG) and iShares U.S. Healthcare Providers ETF (IHF).SPDR S&P 600 Small Cap ETF (SLY).

What guidance has NeoGenomics issued on next quarter's earnings?: NeoGenomics issued an update on its first quarter 2024 earnings guidance on Wednesday, February, 21st. The company provided EPS guidance of for the period. The company issued revenue guidance of $148.0 million-$151.0 million, compared to the consensus revenue estimate of $149.4 million.
What is Douglas M. VanOort's approval rating as NeoGenomics' CEO?: 116 employees have rated NeoGenomics Chief Executive Officer Douglas M. VanOort on Glassdoor.com. Douglas M. VanOort has an approval rating of 98% among the company's employees. This puts Douglas M. VanOort in the top 20% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of NeoGenomics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other NeoGenomics investors own include Marvell Technology (MRVL), NVIDIA (NVDA), Alibaba Group (BABA), Block (SQ), Inseego (INSG), PayPal (PYPL), Micron Technology (MU), Invitae (NVTA), CRISPR Therapeutics (CRSP) and AbbVie (ABBV).
Who are NeoGenomics' major shareholders?: NeoGenomics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Silverberg Bernstein Capital Management LLC (0.02%), Allspring Global Investments Holdings LLC (0.02%) and Banque Cantonale Vaudoise (0.01%). Insiders that own company stock include Alicia C Olivo, Bruce K Crowther, Douglas Matthew Brown, George Cardoza, Kathryn B Mckenzie, Mark Mallon, Robert J Shovlin and William Bonello.
View institutional ownership trends.
How do I buy shares of NeoGenomics?: Shares of NEO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.
Does NeoGenomics have any subsidiaries?: The following companies are subsidiares of NeoGenomics: Clarient Inc., Clarient Diagnostic Services Inc, Clarient Inc, Cynogen Inc., GE Medical Holding AB., Genesis Acquisition Holding Corp, Genesis Acquisition Holdings Corp., Genoptix, Genoptix Inc., Inivata Inc., Inivata Limited, Inivata Limited., Minuet Diagnostics Inc., NeoGenomics Bioinformatics Inc., NeoGenomics Europe SA, NeoGenomics Foundation Inc, NeoGenomics Laboratories Inc, NeoGenomics Singapore Pte. Ltd, Path Labs LLC, Suzhou NeoGenomics Pharmaceutical Research Co. Limited, Trapelo Health, and Trapelo Health LLC.
Read More

This page (NASDAQ:NEO) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

NeoGenomics (NEO) Stock Price, News & Analysis

NeoGenomics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About NeoGenomics Stock (NASDAQ:NEO)

NEO Stock Price History

NEO Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

NEO Stock Analysis - Frequently Asked Questions

Overall MarketRank^™